Please ensure Javascript is enabled for purposes of website accessibility

Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today

By Eric Volkman - Feb 4, 2021 at 6:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company isn't giving up on a promising pipeline drug.

What happened

BrainStorm Cell Therapeutics(BCLI -3.02%) stock price shot up by nearly 30% today, on the one-two punch of an encouraging metric or two in its quarterly results and an update about its most promising pipeline drug.

So what

For BrainStorm's Q4 of 2020, the clinical-stage biotech said that its net loss deepened to $31.8 billion, from the year-ago shortfall of nearly $23.3 million. The company doesn't have revenue; however, it has accumulated a cash pile to keep funding operations -- its cash and cash equivalents stood at $37.8 million, far above the roughly $536,000 of Q4 2019.

Gloved and masked medical researchers using microscopes in their work

Image source: Getty Images.

What was likely a stronger tailwind for the stock on Thursday was BrainStorm's news about NurOwn, its treatment that originally targeted the fatal neurological disease amyotrophic lateral sclerosis (ALS).

Several months after it released lackluster top-line results from a phase 3 study of the treatment, the company now says that it expects positive phase 2 data from a study testing its effects on progressive multiple sclerosis (MS).

BrainStorm added that it expects top-line data from that study by the end of this current quarter.

Now what

BrainStorm's note of confidence on NurOwn is refreshing, given the damp squib of those phase 3 ALS findings. It also holds promise in the fight against progressive MS, a long-term, debilitating illness in which the immune system attacks myelin -- the material that "insulates" nerve cells -- causing often serious damage to various components of the nervous system.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Brainstorm Cell Therapeutics Inc. Stock Quote
Brainstorm Cell Therapeutics Inc.
$2.89 (-3.02%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.